Plutux
$1.56
-0.32%
2026-09-03 16:00:01 EDT-$0.01
Healthcare
Medical - Specialties
NASDAQ
Active Trading

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, ...

Price Action

$1.56
-0.32%-$0.01
High
Low
52W High-47.5%
Rel. vol
Interval
Range6.2h
VolumeSMA5SMA10
Spectral AI, Inc. (Nasdaq: MDAI) is a healthcare technology company headquartered in Dallas, Texas, dedicated to advancing predictive diagnostics through artificial intelligence. Founded in 2009 by Dr. J. Michael DiMaio, the company has evolved from its origins as Spectral MD, Inc. into a public entity focused on wound care management. ...Spectral AI, Inc. (Nasdaq: MDAI) is a healthcare technology company headquartered in Dallas, Texas, dedicated to advancing predictive diagnostics through artificial intelligence. Founded in 2009 by Dr. J. Michael DiMaio, the company has evolved from its origins as Spectral MD, Inc. into a public entity focused on wound care management. The core product, the DeepView System, integrates proprietary AI algorithms with multi-spectral imaging (MSI) technology to assess tissue damage at the initial presentation of a wound, distinguishing between healthy, partially damaged, and fully damaged tissue. The system provides a binary prediction of a wound's healing potential by a future time point, enabling clinicians to make timely and informed treatment decisions. The company's target applications include burn wounds and diabetic ulcers, addressing a significant unmet clinical need. Financially, Spectral AI has a market capitalization of approximately $54 million, with a price-to-sales ratio of 3.59. The company reported a negative net profit margin of -69.3%, reflecting its investment in R&D and commercialization efforts. Key financial metrics indicate a challenging liquidity position, with a current ratio of 0.895 and negative working capital. Despite this, the company has invested heavily in research and development, with R&D expenses representing 50.2% of revenue. The leadership team includes CEO Vincent S. Capone, appointed in February 2026, and co-founder Wensheng Fan, who serves as a key technology leader. The company's strategic focus is on regulatory approvals and market adoption of its predictive diagnostics, aiming to transform wound care through 'Day One' healing predictions. With a team of 65 full-time employees, Spectral AI is positioned as a pioneer in the emerging field of AI-driven medical diagnostics.
Founded
2009
Employees
65
CEO
Vincent S. Capone
Full Name
Spectral AI, Inc.
Sector
Healthcare
Industry
Medical - Specialties
ROE
120.69%
Market Cap
$0.05B
Current Ratio
0.90
WACC
11.03%
ROIC
1168.39%

Contact Information

972-499-4934
2515 McKinney Avenue, Dallas, TX 75201

Related stocksMedical - Specialties

Browse all US stocks

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026